A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Blisibimod (A 623) Administration in Subjects With Systemic Lupus Erythematosus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Blisibimod (A 623) Administration in Subjects With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Blisibimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms CHABLIS-SC1
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 12 Mar 2018 Results (n=442) assessing efficacy and tolerability of blisibimod administered once a week and once every 4-weeks in patients with active systemic lupus erythematosus that is resistant to corticosteroid therapy, were published in the Annals of the Rheumatic Diseases.
    • 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 05 Nov 2017 According to an Anthera Pharmaceuticals media release, additional findings from this trial were presented at the American College of Rheumatology (ACR) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top